Outcomes of autologous hematopoietic stem cell transplantation for patients with Lymphoma at Vinmec Times City Hospital
Main Article Content
Abstract
Autologous hematopoietic stem cell transplantation (auto-HSCT) is applied in various forms of relapsed/refractory lymphoma. This a retrospective case series study was conducted to describe the clinical and laboratory characteristics, as well as treatment outcomes, of 18 lymphoma patients who underwent autologous hematopoietic stem cell transplantation at Vinmec Times City Hospital from January 1, 2022 to July 31, 2025. Most patients presented at stage III (55.56%), with 50.00% having an IPI score of 3. The majority had received ≥2 lines of therapy before transplant. The complete response rate prior to transplant was 83.33%. The median engraftment time was 9.38 ± 0.91 days for neutrophils and 9.83 ± 1.69 days for platelets. No transplant-related mortality was recorded at 1, 2, or 3 years. The mean disease-free survival (DFS) was 18.82 ± 13.21 months. Four patients relapsed at 3, 4, 13, and 25 months post-transplant. The 1-year, 2-year, and 3-year DFS rates were 88.89%, 83.34%, and 77.78%, respectively. The 3-year overall survival (OS) was 100%. Toxicity and relapse-free survival data support autologous stem cell transplantation as a viable option to be performed at specialized centers, remaining the standard of care for relapsed/refractory lymphoma in the current context.
Article Details
Keywords
Relapsed/refractory lymphoma, autologous hematopoietic stem cell transplantation, neutrophil engraftment, platelet engraftment, post-transplant survival
References
2. Nguyễn Văn Hưng, Nguyễn Tuấn Tùng, Phạm Quang Vinh. Nghiên cứu kết quả ghép tế bào gốc tạo máu tự thân ở bệnh nhân u lympho không Hodgkin tế bào B tái phát tại Bệnh viện Bạch Mai. Tạp chí Nghiên cứu Y học. 2021; 140 (4).
3. Wullenkord R, Berning P, Niemann AL, Wethmar K, Bergmann S, Lutz M, et al. The role of autologous stem cell transplantation in aggressive B-cell lymphomas: Real-world data from a retrospective single-center analysis. Ann Hematol. 2021;100:2733-44.
4. Zheng G, He J, Cai Z, et al. A retrospective study of autologous stem cell mobilization by G-CSF in combination with chemotherapy in patients with multiple myeloma and lymphoma. Oncol Lett. 2019; 18 (1): 1051-9.
5. Batgi H, Başci S, Dal MS, et al. Gemcitabine, dexamethasone and cisplatin (GDP) is an effective and well-tolerated mobilization regimen for relapsed and refractory lymphoma: A single-center experience. Turk J Med Sci. 2021; 51: 685-92.
6. Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0, November 2017, National Institutes of Health, National Cancer Institute. Available at: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf (Accessed March 27, 2018).
7. Robert Frank Cornell, Parameswaran Hari, William R. Drobyski. Engraftment Syndrome after Autologous Stem Cell Transplantation: An Update Unifying the Definition and Management Approach. Biology of Blood and Marrow Transplantation. 21 (2015), 2061 - 2068.
8. Mohty M, Malard F, Alaskar AS, et al. Diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a refined classification from the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant. 2023; 58(7): 749-54.
9. Bạch Quốc Khánh. Nghiên cứu hiệu quả của ghép tế bào tự thân điều trị bệnh nhân Đa u tủy xương và U lympho ác tính không Hodgkin”, Luận văn tiến sỹ y học, Đại học y Hà Nội. 2013.
10. Eser A, Timurağaoğlu A. The efficacy and safety of busulfan-etoposide-melphalan regimen in autologous stem cell transplantation in relapsed/refractory Hodgkin and non-Hodgkin lymphoma patients: A single-center experience. Istanbul Med J. 2021; 22 (2): 133-9.
11. Hajifathali A, Mehdizadeh M, Vosoughi T, Tabarraee M, Talebi A, Pezeshki SS, et al. Comparison of survival between Hodgkin and non-Hodgkin lymphoma after autologous stem cell transplantation. Clin Cancer Investig J. 2020; 9(1): 1-6. doi:10.4103/ccij.ccij_112_19.
12. Roerden M, Sökler M, Kanz L, Bethge W, Vogel W, Walz JS. Outcome after autologous stem cell transplantation in primary refractory or relapsed Hodgkin lymphoma: A long-term follow-up single-center experience. Ann Hematol. 2020; 99: 265-76.
13. Beitinjaneh A, Saliba RM, Medeiros LJ, Turturro F, Rondon G, Korbling M, et al. Comparison of survival in patients with T cell lymphoma after autologous and allogeneic stem cell transplantation as a frontline strategy or in relapsed disease. Biol Blood Marrow Transplant. 2015; 21: 855-9.
14. Yıldız E, Çetin G, Pasin Ö. Survival outcomes of autologous stem cell transplantation in lymphoma patients. Hematol Transfus Cell Ther. 2024; 46 (Suppl 7):S29-31.